Controversial findings on calcium channel blockers (CCBs) safety, particularly nifedipine, are debated. Re-analyses suggest no significant mortality difference, but further studies on long-acting CCBs are needed.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background: